Epigenetic Dysregulation of Myeloproliferative Neoplasms.
Epigenetic pathways
Epigenetics of MPN
Fibrotic progression
Myelofibrosis
Myeloproliferative neoplasms
Preclinical studies
Journal
Hematology/oncology clinics of North America
ISSN: 1558-1977
Titre abrégé: Hematol Oncol Clin North Am
Pays: United States
ID NLM: 8709473
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
entrez:
1
3
2021
pubmed:
2
3
2021
medline:
4
3
2022
Statut:
ppublish
Résumé
This article reviews the genetic data on epigenetic modifying mutations in myeloproliferative neoplasms and their clinical implications, preclinical studies exploring our current understanding of how mutations in epigenetic modifying proteins cooperate with myeloproliferative neoplasms drivers to promote disease progression, and recent advances in novel therapeutics supporting the role of targeting epigenetic pathways to treat fibrotic progression.
Identifiants
pubmed: 33641866
pii: S0889-8588(21)00001-0
doi: 10.1016/j.hoc.2021.01.001
pmc: PMC7927771
mid: NIHMS1660548
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
237-251Subventions
Organisme : NCI NIH HHS
ID : P01 CA108671
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The authors acknowledge the support of Memorial Sloan Kettering Cancer Center Support Grant NIHP30 CA008748. This work was supported by National Cancer InstituteP01 CA108671 11 (R.L.L.) and the Janus Fund (O.S. and R.L.L.). R.L.L. is on the supervisory board of Qiagen and is a scientific advisor to Imago, Mission Bio, Zentalis, Ajax, Auron, Prelude, C4 Therapeutics and Isoplexis. He receives research support from and consulted for Celgene and Roche and has consulted for Incyte, Janssen, Astellas, Morphosys and Novartis. He has received honoraria from Roche, Lilly and Amgen for invited lectures and from Gilead for grant reviews.
Références
Nat Rev Drug Discov. 2014 Sep;13(9):673-91
pubmed: 25131830
J Hematol Oncol. 2017 Jul 11;10(1):139
pubmed: 28697759
Hemasphere. 2018 Jun 08;2(3):e54
pubmed: 31723778
Blood. 2018 Aug 23;132(8):791-803
pubmed: 29991556
N Engl J Med. 2015 Feb 12;372(7):601-612
pubmed: 25671252
Blood. 2014 Jul 3;124(1):151-2
pubmed: 24993879
Leukemia. 2010 Jul;24(7):1302-9
pubmed: 20508616
Cancers (Basel). 2020 Aug 07;12(8):
pubmed: 32784800
Cancer Discov. 2020 Nov;10(11):1742-1757
pubmed: 32669286
Leukemia. 2008 May;22(5):965-70
pubmed: 18385750
Leukemia. 2013 Sep;27(9):1861-9
pubmed: 23619563
Cancer Cell. 2011 Feb 15;19(2):283-94
pubmed: 21316606
Leukemia. 2014 Sep;28(9):1804-10
pubmed: 24549259
Nat Rev Cancer. 2012 Sep;12(9):599-612
pubmed: 22898539
Cancer Discov. 2018 Jan;8(1):24-36
pubmed: 29263030
Cancer Discov. 2019 Jun;9(6):778-795
pubmed: 30944118
Blood. 2020 Jan 16;135(3):191-207
pubmed: 31750881
Blood. 2018 May 10;131(19):2111-2119
pubmed: 29572380
Nature. 2009 Oct 8;461(7265):819-22
pubmed: 19783980
J Clin Invest. 2018 Feb 1;128(2):789-804
pubmed: 29355841
Cancer Res. 2013 Feb 1;73(3):1076-85
pubmed: 23066032
Br J Haematol. 2013 Apr;161(1):68-75
pubmed: 23330839
Blood Adv. 2016 Nov 30;1(2):105-111
pubmed: 29296803
Blood. 2009 Dec 3;114(24):5024-33
pubmed: 19828702
N Engl J Med. 2012 Mar 1;366(9):799-807
pubmed: 22375971
Cancer Cell. 2018 Jan 8;33(1):29-43.e7
pubmed: 29249691
Blood Adv. 2016 Nov 22;1(1):21-30
pubmed: 29296692
N Engl J Med. 2010 Jan 28;362(4):369-70
pubmed: 20107228
Blood Adv. 2020 Nov 10;4(21):5336-5342
pubmed: 33112940
Cell Mol Life Sci. 2019 Jul;76(13):2511-2523
pubmed: 30927018
Nat Rev Cancer. 2006 Nov;6(11):846-56
pubmed: 17060944
Genes Chromosomes Cancer. 2012 Aug;51(8):743-55
pubmed: 22489043
Blood Adv. 2017 Sep 08;1(20):1729-1738
pubmed: 29296819
Nature. 2006 Feb 16;439(7078):871-4
pubmed: 16357870
J Exp Med. 2018 Jun 4;215(6):1729-1747
pubmed: 29643185
Leukemia. 2019 May;33(5):1287-1291
pubmed: 30651633
Nat Immunol. 2017 Mar 22;18(4):374-384
pubmed: 28323260
Blood. 2015 Jan 8;125(2):327-35
pubmed: 25281607
Blood. 2012 Apr 19;119(16):3779-89
pubmed: 22408262
Cell Stem Cell. 2018 Feb 1;22(2):157-170
pubmed: 29395053
Leukemia. 2012 Mar;26(3):475-80
pubmed: 21912393
Blood. 2018 Oct 18;132(16):1664-1674
pubmed: 30185431
Cancer Cell. 2012 Aug 14;22(2):180-93
pubmed: 22897849
Cancers (Basel). 2020 Aug 06;12(8):
pubmed: 32781570
J Exp Med. 2016 Jul 25;213(8):1459-77
pubmed: 27401345
Leukemia. 2010 Jun;24(6):1146-51
pubmed: 20410924
N Engl J Med. 2018 Oct 11;379(15):1416-1430
pubmed: 30304655
Blood. 2020 Jul 2;136(1):61-70
pubmed: 32430500
Blood. 2015 Aug 6;126(6):790-7
pubmed: 26124496
Cold Spring Harb Perspect Med. 2017 May 1;7(5):
pubmed: 28159832
Leukemia. 2019 Jan;33(1):191-204
pubmed: 29967380
Biol Blood Marrow Transplant. 2019 Jun;25(6):1142-1151
pubmed: 30625392
Haematologica. 2019 Aug;104(8):1572-1579
pubmed: 30655376
J Exp Med. 2013 Nov 18;210(12):2641-59
pubmed: 24218140
Leukemia. 2017 Mar;31(3):678-687
pubmed: 27677740
Blood. 2018 Jan 18;131(3):328-341
pubmed: 29113963
Future Oncol. 2018 Apr;14(10):979-993
pubmed: 29543066
Clin Cancer Res. 2013 Nov 15;19(22):6230-41
pubmed: 24081976
Leuk Lymphoma. 2019 Jul;60(7):1767-1774
pubmed: 30632841
Blood. 2016 Jun 30;127(26):3410-23
pubmed: 27081096
Mol Cell. 2019 Mar 21;73(6):1292-1305.e8
pubmed: 30765193
J Exp Med. 2016 Jul 25;213(8):1479-96
pubmed: 27401344
Blood. 2014 Apr 3;123(14):2220-8
pubmed: 24478400
N Engl J Med. 2014 Dec 25;371(26):2488-98
pubmed: 25426837
Leukemia. 2012 Sep;26(9):2039-51
pubmed: 22699452
Haematologica. 2013 Sep;98(9):1414-20
pubmed: 23716560
Sci Rep. 2017 Jul 28;7(1):6774
pubmed: 28754985
Biol Blood Marrow Transplant. 2017 Jul;23(7):1095-1101
pubmed: 28389256
Cell Stress. 2020 Jul 13;4(8):199-215
pubmed: 32743345
Blood. 2015 Jan 8;125(2):304-15
pubmed: 25395421
Blood. 2018 Dec 27;132(26):2707-2721
pubmed: 30366920